Clinical Trial Update: Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating daratumumab for proliferative glomerulonephritis with monoclonal IgG deposits is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Glomerulonephritis with Monoclonal Igg Deposits

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits | Phase 2 | Status: RECRUITING